These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Hansen JB; Sandset PM; Huseby KR; Huseby NE; Bendz B; Ostergaard P; Nordøy A Br J Haematol; 1998 Jun; 101(4):638-46. PubMed ID: 9674734 [TBL] [Abstract][Full Text] [Related]
4. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease. Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809 [TBL] [Abstract][Full Text] [Related]
5. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Brown JR; Kuter DJ Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705 [TBL] [Abstract][Full Text] [Related]
6. The present status of tissue factor pathway inhibitor. Lindahl AK; Sandset PM; Abildgaard U Blood Coagul Fibrinolysis; 1992 Aug; 3(4):439-49. PubMed ID: 1420819 [TBL] [Abstract][Full Text] [Related]
7. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880 [TBL] [Abstract][Full Text] [Related]
8. Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration. Cella G; Cipriani A; Tommasini A; Rampin E; Sbarai A; Rocconi R; Mazzaro G; Luzzatto G Semin Thromb Hemost; 1997; 23(1):45-9. PubMed ID: 9156410 [TBL] [Abstract][Full Text] [Related]
9. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants. Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547 [TBL] [Abstract][Full Text] [Related]
10. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840 [TBL] [Abstract][Full Text] [Related]
12. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Hansen JB; Svensson B; Olsen R; Ezban M; Osterud B; Paulssen RH Thromb Haemost; 2000 Jun; 83(6):937-43. PubMed ID: 10896252 [TBL] [Abstract][Full Text] [Related]
13. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Alban S; Gastpar R Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675 [TBL] [Abstract][Full Text] [Related]
14. Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbits. Warn-Cramer BJ; Maki SL; Rapaport SI Thromb Haemost; 1993 Mar; 69(3):221-6. PubMed ID: 8470044 [TBL] [Abstract][Full Text] [Related]
15. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies. Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186 [TBL] [Abstract][Full Text] [Related]
16. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Alban S Semin Thromb Hemost; 2001 Oct; 27(5):503-11. PubMed ID: 11668420 [TBL] [Abstract][Full Text] [Related]
17. Tissue factor pathway inhibitor release and depletion by sulodexide in humans. Borawski J; Gozdzikiewicz J; Dubowski M; Pawlak K; Mysliwiec M Adv Med Sci; 2009; 54(1):32-6. PubMed ID: 19731406 [TBL] [Abstract][Full Text] [Related]
18. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. Liestøl S; Sandset PM; Jacobsen EM; Mowinckel MC; Wisløff F Br J Haematol; 2007 Jan; 136(1):131-7. PubMed ID: 17092306 [TBL] [Abstract][Full Text] [Related]
19. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels. Agledahl I; Brodin E; Svartberg J; Hansen JB Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Bregengaard C; Nordfang O; Ostergaard P; Petersen JG; Meyn G; Diness V; Svendsen O; Hedner U Thromb Haemost; 1993 Sep; 70(3):454-7. PubMed ID: 8259548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]